Vertex Pharmaceuticals (MEX:VRTX) Ending Cash Position: MXN99,268 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MEX:VRTX Vertex Pharmaceuticals Inc MEX:VRTX
92 GF Score
Price MXN8,319.00
GF Value MXN8,653.88
Valuation Fairly Valued
! 5 Warning Signs
View Full Analysis

What is Vertex Pharmaceuticals Ending Cash Position?

Vertex Pharmaceuticals MEX:VRTX 92 Ending Cash Position is MXN99,268 Mil as of Mar. 2026. GuruFocus rates MEX:VRTX with a GF Score™ of 92/100 and a GF Value™ of MXN8,653.88 (Fairly Valued). The stock has 5 warning signs investors should review.

Vertex Pharmaceuticals's Ending Cash Position for the quarter that ended in Mar. 2026 was MXN99,268 Mil.

Vertex Pharmaceuticals's quarterly Ending Cash Position increased from Sep. 2025 (MXN90,763 Mil) to Dec. 2025 (MXN91,609 Mil) and increased from Dec. 2025 (MXN91,609 Mil) to Mar. 2026 (MXN99,268 Mil).

Vertex Pharmaceuticals's annual Ending Cash Position declined from Dec. 2023 (MXN176,062 Mil) to Dec. 2024 (MXN95,356 Mil) and declined from Dec. 2024 (MXN95,356 Mil) to Dec. 2025 (MXN91,609 Mil).

Vertex Pharmaceuticals Ending Cash Position Related Terms

Vertex Pharmaceuticals Ending Cash Position Historical Data

* Premium members only.

The historical data trend for Vertex Pharmaceuticals's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Vertex Pharmaceuticals Ending Cash Position Chart

Vertex Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Ending Cash Position
Get a 7-Day Free Trial Premium Member Only Premium Member Only 139,497.25 204,941.95 176,061.99 95,356.43 91,609.40

Vertex Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Ending Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 95,854.85 93,807.07 90,763.43 91,609.40 99,268.21
MEX:VRTX
92GF Score
Vertex Pharmaceuticals Inc MEX:VRTX
Ending Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Vertex Pharmaceuticals Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Vertex Pharmaceuticals's Ending Cash Position for the fiscal year that ended in Dec. 2025 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=82325.662+9283.739
=91,609

Vertex Pharmaceuticals's Ending Cash Position for the quarter that ended in Mar. 2026 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=91746.771+7521.439
=99,268

Frequently Asked Questions Learn more about Ending Cash Position →
What does a Ending Cash Position of MXN99,268 Mil mean?
Vertex Pharmaceuticals (MEX:VRTX) has a Ending Cash Position of MXN99,268 Mil as of Mar. 2026. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Vertex Pharmaceuticals and its competitors.
Is Vertex Pharmaceuticals' Ending Cash Position too high?
Vertex Pharmaceuticals' current Ending Cash Position is MXN99,268 Mil. Overall, Vertex Pharmaceuticals has a GF Score™ of 92/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Vertex Pharmaceuticals' Ending Cash Position compare to REGN and ALNY?
Vertex Pharmaceuticals' Ending Cash Position of MXN99,268 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Ending Cash Position for a Biotechnology company?
A good Ending Cash Position depends on the Biotechnology industry context. However, Ending Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Ending Cash Position mean?
A high Ending Cash Position can signal that a stock is expensive relative to its fundamentals. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Vertex Pharmaceuticals and its competitors. Vertex Pharmaceuticals's current Ending Cash Position is MXN99,268 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vertex Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Vertex Pharmaceuticals (MEX:VRTX) is currently considered Fairly Valued. The stock's GF Value™ is MXN8,653.88, compared to a current price of MXN8,319.00 — trading 3.9% below its estimated fair value. The current Ending Cash Position is MXN99,268 Mil. Vertex Pharmaceuticals' overall GF Score™ is 92/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Ending Cash Position calculated?
Ending Cash Position is calculated from a company's financial statements. For Vertex Pharmaceuticals (MEX:VRTX), the current Ending Cash Position is MXN99,268 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Vertex Pharmaceuticals (MEX:VRTX) Overvalued in 2026?

Based on GuruFocus' analysis, Vertex Pharmaceuticals stock appears to be undervalued. The current stock price of MXN8,319.00 is trading 3.9% below its estimated GF Value™ of MXN8,653.88. GuruFocus considers Vertex Pharmaceuticals to be Fairly Valued.

Key valuation signals for MEX:VRTX:

  • Ending Cash Position: MXN99,268 Mil
  • GF Value™: MXN8,653.88 vs. price of MXN8,319.00 (3.9% below fair value)
  • GF Score™: 92/100 with 5 warning signs

No single metric tells the full story. See the MEX:VRTX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Vertex Pharmaceuticals Business Description

Address 50 Northern Avenue, Boston, MA, USA, 02210
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease, and Journavx, a non-opioid pain medication approved for the treatment of moderate-to-severe acute pain in adults. Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
92GF Score

Get the complete analysis for MEX:VRTX

Ending Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN8,319.00
Price
MXN8,653.88
GF Value